

Walter Hanel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11857797/publications.pdf>

Version: 2024-02-01

18
papers

567
citations

1040056

9
h-index

1058476

14
g-index

18
all docs

18
docs citations

18
times ranked

1345
citing authors

#	ARTICLE	IF	CITATIONS
1	Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. <i>Hematological Oncology</i> , 2022, 40, 49-57.	1.7	2
2	Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias. <i>Frontiers in Oncology</i> , 2022, 12, 858426.	2.8	0
3	Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions. <i>Journal of Clinical Medicine</i> , 2022, 11, 2699.	2.4	4
4	Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies. <i>Journal of Hematology and Oncology</i> , 2021, 14, 104.	17.0	13
5	Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis. <i>Hematological Oncology</i> , 2021, 39, 473-482.	1.7	5
6	PRMT5 Inhibition Modulates E2F1 and P53 to Restore Cell Cycle Regulation and Drive DNA Damage Response in Ibrutinib-Resistant Mantle Cell Lymphoma. <i>Blood</i> , 2021, 138, 787-787.	1.4	0
7	Transducin β -like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2927-2939.	3.5	5
8	Emerging therapies in mantle cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 79.	17.0	33
9	Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma. <i>Blood</i> , 2020, 136, 15-16.	1.4	0
10	A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma. <i>Blood</i> , 2020, 136, 29-29.	1.4	2
11	Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas. <i>Oncotarget</i> , 2017, 8, 114474-114480.	1.8	15
12	A retrospective comparative outcome analysis following systemic therapy in <i>Mycosis fungoides</i> and <i>Sézary syndrome</i> . <i>American Journal of Hematology</i> , 2016, 91, E491-E495.	4.1	41
13	Links between mutant p53 and genomic instability. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 433-439.	2.6	162
14	SEF/IL-17R (SEFIR) Is Not Enough. <i>Journal of Biological Chemistry</i> , 2010, 285, 32751-32759.	3.4	50
15	Subunit Dynamics in the IL-17 Receptor Complex: Identification of a Pre-Ligand Assembly Domain (PLAD) and Ligand Binding site in IL-17RA. <i>FASEB Journal</i> , 2008, 22, 1069.1.	0.5	0
16	Cutting Edge: Identification of a Pre-Ligand Assembly Domain (PLAD) and Ligand Binding Site in the IL-17 Receptor. <i>Journal of Immunology</i> , 2007, 179, 6379-6383.	0.8	45
17	CARMA1 Coiled-coil Domain Is Involved in the Oligomerization and Subcellular Localization of CARMA1 and Is Required for T Cell Receptor-induced NF- κ B Activation. <i>Journal of Biological Chemistry</i> , 2007, 282, 17141-17147.	3.4	53
18	Distinct functional motifs within the IL-17 receptor regulate signal transduction and target gene expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 7506-7511.	7.1	137